GenSight Biologics S.A.

SIGHT

FR0013183985

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:12 2024-05-10 EDT			5-day change	1st Jan Change
0.391 ^EUR	-2.37%		-1.01%	-15.00%

05-07	GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding	CI
04-05	GenSight: financial visibility assured until the end of April	CF

GenSight Biologics S.A. announced that it has received ?4 million in funding from Sofinnova Partners SAS, The Invus Group, LLC, UPMC Enterprises

November 12, 2023

On November 13, 2023, GenSight Biologics S.A. closed the transaction. The company announced that it has received ?4 million in its second tranche.

Latest news about GenSight Biologics S.A.

GenSight Biologics S.A. announced that it expects to receive ?1.546199 million in funding	05-06	CI
GenSight: financial visibility assured until the end of April	04-05	CF
GenSight: share price falls, limited financial visibility	03-25	CF
GenSight Biologics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-22	CI
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ®? Injections Four Years After One-Time Administration	03-20	CI
GenSight Biologics: results on Lumevoq® gene therapy	03-12	CF
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024	03-12	CI
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024	03-06	CI
GenSight: Goldman Sachs exceeds 5% threshold	02-16	CF
GenSight Biologics Raises EUR5 Million Fresh Capital from New, Existing Investors	02-08	MT
Gensight Biologics S.A. Announces CFO Changes	01-25	CI
GenSight Biologics Announces Board Changes	01-16	CI
GenSight: UK notice keeps hopes alive	12-27	CF
GenSight appoints new CEO	12-22	CF
France's GenSight Biologics Appoints New CEO	12-22	MT
GenSight Biologics S.A. Announces CEO Changes	12-22	CI
GenSight: Sofinnova Partners exceeds 20% stake	11-27	CF
GenSight: CDC falls below 5% stake	11-27	CF
GenSight Biologics Raises EUR4.7 Million via Private Placement, Public Offering	11-21	MT
Gensight Biologics S.A. Confirms Second Successful GMP Batch of Lumevoq	11-15	CI
GenSight: a breath of fresh air with new financing	11-13	CF
GenSight Biologics S.A. Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch	11-13	CI
GenSight Biologics S.A. announced that it has received ?4 million in funding from Sofinnova Partners SAS, The Invus Group, LLC, UPMC Enterprises	11-12	CI
European Medicines Regulator OKs Study Protocol for Gensight Biologics' Late-stage Trial of Vision Loss Drug; Stock Surges	23-09-27	MT
GenSight: market hails progress on Lumevoq	23-09-27	CF

GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2023, the company had a portfolio of 2 products, including 1 in phase III clinical development (Lumevoq for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for GenSight Biologics S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.391 EUR

Average target price

0.4 EUR

Spread / Average Target

+2.30%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENSIGHT BIOLOGICS S.A.	-15.00%	32.86M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs